Here’s a fact that doesn’t get said out loud enough: heart disease is the leading cause of death in women, and the years surrounding menopause are when the trajectory toward it actually gets set. Not at 65. Not “eventually.” Now, in the stretch of roughly five years bracketing your final period. 🫀 We’ve written before about the perimenopause longevity checklist and the many systems that shift during this decade. This time we’re going deep on one system in particular, because 2025 and 2026 delivered a stack of new evidence, plus a genuinely stunning regulatory reversal, that changes what “doing something about it” actually looks like.
Why your arteries notice menopause before you do
The idea that heart risk “starts” at menopause is outdated. It starts earlier, and the Study of Women’s Health Across the Nation (SWAN) has the receipts. In one analysis of 249 women aged 42 to 52 at the Pittsburgh site, researchers used repeated ultrasounds to track the carotid artery through the menopause transition. During late perimenopause, defined as three or more months without a period, artery wall thickness increased by an average of 0.017 millimeters a year and diameter by 0.024 millimeters a year, both significantly faster than during the premenopausal years. Lead author Samar El Khoudary described late perimenopause as a stage of vascular remodeling, when arteries become measurably more vulnerable regardless of a woman’s age or ethnicity.
That’s not the only marker moving. A separate SWAN Heart ancillary study followed 411 women for an average of 2.3 years and found that those going through the transition had faster increases in aortic pulse wave velocity, a measure of arterial stiffness, than women who stayed premenopausal or postmenopausal throughout. And a third SWAN analysis of 471 women found a steep rise in LDL cholesterol particles clustered tightly around the final menstrual period, with higher LDL particle counts and apolipoprotein B tracking with more coronary calcium and thicker carotid walls later on. 🔬
The mechanism isn’t mysterious. Estrogen keeps arteries flexible, helps regulate cholesterol clearance, and calms inflammation. When it falls, all three jobs go undone at once. Quick recap of what tends to move during this window:
LDL cholesterol and apolipoprotein B, often up 10 to 15 percent
Carotid artery thickness and diameter
Aortic pulse wave velocity (arterial stiffness)
Visceral, abdominal fat distribution
Blood pressure, in some but not all cohorts
Worth sitting with: none of this requires you to feel anything. These are silent, measurable shifts that show up on imaging and blood work well before symptoms would ever prompt a visit to a cardiologist.
The five years that do the most damage
So why five years specifically, and not ten, or twenty? Because that’s roughly where the data clusters. Longitudinal research on lipid changes shows the sharpest movement in LDL-C, apolipoprotein B, and triglycerides happening in the two years surrounding the final menstrual period, with some cohorts showing the effect stretching out to six years afterward. A separate retrospective study compared 90 postmenopausal women scanned within their first five years of menopause against 90 age- and BMI-matched women scanned during years five through ten. The later group had a significantly higher android-to-gynoid fat ratio (a marker of the more dangerous, apple-shaped fat distribution) and a modestly but statistically significantly higher ten-year cardiovascular risk score, 3.74 percent versus 3.28 percent. Small numbers, but a real, measurable divergence that keeps building with time since your last period.
Context matters here, and how menopause arrives changes the math considerably. A large cohort study out of Northwestern Medicine found that women who go through natural menopause before age 40 face roughly a 40 percent higher lifetime risk of coronary heart disease compared with women who reach menopause later, a gap that held even after adjusting for smoking, obesity, hypertension, and diabetes. Cardiologist Amy Freaney, who worked on the study, put it plainly: women with premature menopause need to treat it as an early flag, not a footnote, and bring it up with their doctor directly rather than waiting to be asked. 💊
A few things to flag honestly, because LongevityHub doesn’t do vague optimism: this is mostly observational data, meaning it shows strong association, not airtight proof that menopause itself, independent of aging, causes every one of these changes. And the “five years” framing is a synthesis of several overlapping windows (two years, six years, ten years) rather than one single trial with a five-year cutoff stamped on it. What’s consistent across all of them is the direction: the changes are real, they’re concentrated in the years right around the transition, and they compound the longer they go unaddressed. Have you had your cholesterol or ApoB checked since your cycle started changing? If the honest answer is “not recently,” you’re not alone, and it’s worth fixing this year rather than next.
The FDA just rewrote the rulebook, and not everyone is cheering
This is the part that makes late 2025 a genuinely different moment for this topic. On November 10, 2025, the FDA announced it would remove the black box warnings, the highest-level safety label the agency uses, from hormone therapy products containing estrogen, striking references to cardiovascular disease, breast cancer, and probable dementia risk. The agency is keeping the boxed warning for endometrial cancer on systemic estrogen-only products. Labels are expected to be rewritten within six months to include age-specific guidance reflecting what’s become known as the timing hypothesis: that starting hormone therapy within about ten years of menopause onset, or before age 60, is associated with a more favorable cardiovascular profile, while starting it later is linked to higher risk.
The evidence behind this isn’t new so much as re-read. Subgroup analyses of the original Women’s Health Initiative trial found that women who started hormone therapy within that early window showed trends toward reduced coronary heart disease, hazard ratios of 0.76 for estrogen plus progestin and 0.59 for estrogen alone, though the first of those didn’t reach statistical significance. The randomized ELITE trial added more direct mechanistic support, showing that estradiol slowed atherosclerosis progression in early postmenopausal women but not in those further out from menopause. LongevityHub Pro turns individual breakthroughs like this one into a searchable, connected picture of where the field is actually heading, which is genuinely useful once you start noticing how many separate strands, WHI subgroups, ELITE, KEEPS, DOPS, feed into a single label change.
Not everyone thinks the FDA got the process right. Adriane Fugh-Berman, a pharmacology professor at Georgetown, told NPR the panel that recommended the change felt like “theater, not scientific evaluation,” arguing the agency skipped its usual rigor. That’s a fair caution to hold alongside the excitement: an association found in decades-old subgroup analyses is not the same thing as a fresh, purpose-built randomized trial, and individual risk still depends heavily on your personal and family history of clots, hormone-sensitive cancers, and existing cardiovascular disease. 🧬
What to actually do in this window
None of this is an argument that everyone should start hormone therapy, and it’s not medical advice tailored to you specifically, it’s a case for taking the conversation seriously and having it with real numbers in hand rather than vague worry. A few concrete moves:
Get a full lipid panel done, and ask specifically about apolipoprotein B rather than just LDL, since it’s a sharper predictor. We’ve broken down why ApoB matters more than standard cholesterol if you want the deeper explanation
Know roughly how many years out from your final period you are. It’s the single number that changes the entire hormone therapy risk calculation
Ask your doctor to run a formal ASCVD risk score, not just a gut check based on your age
If cardio has fallen off since perimenopause symptoms started, Zone 2 training is one of the most evidence-backed, low-drama ways back in
Bring your family history of premature menopause, early heart disease, and clotting disorders to the appointment. It changes the calculus more than almost anything else
This window closes quietly. Nobody sends a reminder when you’re two years past your last period versus seven. The women who come out the other side of this decade with the best numbers tend to be the ones who checked in on their heart proactively rather than waiting for a symptom to force the issue. So: when did you last actually look at your numbers, and are you willing to book that appointment this month instead of someday?